For the year ending 2025-12-31, LNTH had -$553,660K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Gain on interest rate swap termination | - | 0 | 0 | 5,494 |
| Net income | 233,559 | 312,442 | 326,661 | 28,067 |
| Depreciation, amortization and accretion | 70,098 | 64,624 | 60,043 | 47,929 |
| Changes in fair value of contingent assets and liabilities | - | -2,699 | -9,275 | 34,700 |
| Impairment of long-lived assets | 0 | 0 | 138,050 | - |
| Adjustment to the fair value of asset retirement obligation | -4,727 | - | - | - |
| Amortization of debt-related costs | 4,457 | 4,296 | 4,300 | 1,249 |
| Change in fair value of contingent assets and liabilities | -1,379 | - | - | - |
| Impairment of long-lived assets | - | - | - | 0 |
| Inventory adjustments | 2,202 | -904 | 7,914 | 7,145 |
| Loss on extinguishment of debt | - | 0 | 0 | -588 |
| Stock-based compensation | 85,563 | 76,393 | 50,507 | 29,262 |
| Gain on disposal of assets | 0 | 8,415 | 51,789 | 0 |
| Gain on sale of relistor licensed intangible asset | 5,000 | - | - | - |
| Unrealized loss on investment in equity securities | -8,617 | -43,564 | - | - |
| Charges incurred pursuant to acquired in-process research and development | -11,212 | -66,000 | 0 | -260,000 |
| Deferred taxes | 21,595 | -30,029 | -55,632 | -48,016 |
| Long-term indemnification receivable | 0 | 0 | -3,929 | -9,554 |
| Long-term income tax payable and other long-term liabilities | 246 | 5,236 | -3,103 | -12,477 |
| Other long-term assets | - | 0 | 0 | 533 |
| Other, net | -5,174 | -12,194 | -4,855 | -4,059 |
| Other current assets | - | -4,440 | 2,418 | 2,440 |
| Accounts receivable | 17,888 | 37,685 | 68,637 | 128,460 |
| Inventory | 9,366 | 2,670 | 36,220 | 7,508 |
| Other current and noncurrent assets | 5,406 | - | - | - |
| Accounts payable | -2,492 | -8,804 | 17,189 | 301 |
| Acquisition of assets | - | - | 45,345 | 260,000 |
| Asset retirement obligation acceleration | - | 0 | 0 | 280 |
| Accrued expenses and other current and long-term liabilities | -9,082 | 46,767 | -81,114 | 63,575 |
| Lending on bridge loan | - | - | - | 0 |
| Net cash provided by operating activities | 390,141 | 544,750 | 305,260 | 281,781 |
| Capital expenditures | 36,089 | 51,625 | 46,555 | 18,347 |
| Acquisition of in-process research and development | 5,413 | - | - | - |
| Proceeds from sale of assets | 0 | 17,767 | 97,839 | 1,800 |
| Acquisition of assets, net | 0 | 80,911 | - | - |
| Acquisition, net of cash acquired-Evergreen Theragnostics | 268,933 | - | - | - |
| Acquisition, net of cash acquired-Life Molecular Imaging Ltd | 306,733 | - | - | - |
| Purchases of investment in equity securities | 10,000 | 83,246 | - | - |
| Cash acquired in acquisition of business | - | - | - | 0 |
| Acquisition of exclusive license option | 0 | 28,000 | - | - |
| Net cash (used in) provided by investing activities | -627,168 | -226,015 | 5,939 | -276,547 |
| Proceeds from interest rate swap termination | - | 0 | 0 | 5,583 |
| Payments of long-term debt and other borrowings | 1,110 | 318 | 717 | 175,385 |
| Deferred financing costs | 0 | 2,331 | 0 | 2,315 |
| Proceeds from stock option exercises | 7,154 | 3,278 | 3,816 | 7,537 |
| Proceeds from issuance of long-term debt, net | - | 0 | 0 | 557,750 |
| Contingent value rights settlement | 0 | 0 | 3,700 | - |
| Proceeds from issuance of common stock | - | 3,450 | 1,933 | 1,375 |
| Proceeds from employee stock purchase plan | 3,727 | - | - | - |
| Payments for minimum statutory tax withholding related to net share settlement of equity awards | 26,338 | 22,615 | 14,394 | 7,759 |
| Equity issuance costs | - | - | - | 0 |
| Debt issuance costs | - | 0 | 0 | 95 |
| Repurchase of common stock | 300,017 | 100,000 | 0 | 75,000 |
| Net cash used in financing activities | -316,584 | -118,536 | -13,062 | 311,691 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -49 | -998 | -93 | -335 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -553,660 | 199,201 | 298,044 | 316,590 |
| Cash, cash equivalents and restricted cash, beginning of period | 914,486 | - | - | - |
| Cash, cash equivalents and restricted cash, end of period | 360,826 | - | - | - |
Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings, Inc. (LNTH)